[1] Rios-Tamayo R,Krsnik I,Gomez-Bueno M,et al.AL Amyloidosis and multiple myeloma:A complex scenario in which cardiac involvement remains the key prognostic factor[J]. Life (Basel),2023,13(7):1518. [2] Padala S A,Barsouk A,Barsouk A,et al.Epidemiology,staging,and management of multiple myeloma[J]. Med Sci (Basel),2021,9(1):3 [3] Liu J,Liu W,Mi L,et al.Incidence and mortality of multiple myeloma in China,2006-2016:An analysis of the Global Burden of Disease Study 2016[J]. J Hematol Oncol,2019,12(1):136. [4] Carlisi M,Mancuso S,Lo PR,et al.High output heart failure in multiple myeloma:Pathogenetic considerations[J]. Cancers (Basel),2022,14(3):610. [5] Javaid S,Frasier K,Chaudhary A J,et al.The burden of heart failure and its impact on mortality and outcomes in hospitalized multiple myeloma patients:A nationwide study[J]. Cureus,2023,15(10):e47570. [6] Proskuriakova E,Jada K,Kakieu DS,et al.Mechanisms and potential treatment options of heart failure in patients with multiple myeloma[J]. Cureus,2021,13(6):e15943. [7] Rahman MR,Ball S,Paz P,et al.Heart failure with carfilzomib in patients with multiple myeloma:A meta-analysis of randomized controlled trials[J]. J Card Fail,2021,27(5):610-612. [8] Bloom MW,Gorevic PD. Cardiac amyloidosis[J]. Ann Intern Med,2023,176(3):ITC33-ITC48. [9] El-Cheikh J,Moukalled N,Malard F,et al.Cardiac toxicities in multiple myeloma:An updated and a deeper look into the effect of different medications and novel therapies[J]. Blood Cancer J,2023,13(1):83. [10] Lyon A R,Dent S,Stanway S,et al.Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies:A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society[J]. Eur J Heart Fail,2020,22(11):1945-1960. [11] Bridoux F,Leung N,Belmouaz M,et al.Management of acute kidney injury in symptomatic multiple myeloma[J]. Kidney Int,2021,99(3):570-580. [12] Lee DH,Kumar A,Mohammed T,et al.Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma[J]. Blood Adv,2023,7(16):4247-4257. [13] Yuan S,Zhou JY,Yang BZ,et al.Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma:Development and validation of a risk score prognostic model[J]. Front Oncol,2023,13:1043869. |